Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2: an Outcome Study
Edith Huland1, A. Burger2, J. Fleischer3, P. Fornara4, E. Hatzmann5, A. Heidenreich6, H. Heinzer1, H. Heynemann4, L. Hoffmann7, R. Hofmann6, H. Huland1, I. Kämpfer7, M. Kindler2, H. Kirchner8, G. Mehlhorn9, T. H. Moniak9, U. Rebmann9, J. Roigas10, T. H. Schneider4, D. Schnorr10, H.-J. Schmitz3, R. Wenisch3, Z. Varga6, J. Vinke5
1Department of Urology, University Hospital Hamburg-Eppendorf, Germany 2Onkologische Schwerpunktpraxis, Berlin, Germany 3St. Carolus Krankenhaus, Görlitz, Germany 4Martin-Luther-Universität Halle-Wittenberg, Halle, Germany 5Chiron BV, Amsterdam 6Philipps-Universität Marburg, Marburg, Germany 7Waldklinikum GmbH, Gera, Germany 8Klinikum Siloah, Germany 9Diakonissenkrankenhaus, Dessau, Germany 10Department of Urology, Charite, Humboldt Universität Berlin, Germany
